# Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure

> **NCT06918912** · PHASE2 · RECRUITING · sponsor: **Istituto Clinico Humanitas** · enrollment: 50 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma
- High-grade B-cell Lymphoma (HGBCL)
- B-Cell Lymphoma Treatment
- Relapsed or Refractory Lymphoma

## Interventions

- **DRUG:** Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate)

## Key facts

- **NCT ID:** NCT06918912
- **Lead sponsor:** Istituto Clinico Humanitas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-16
- **Primary completion:** 2025-03-04
- **Final completion:** 2027-06
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06918912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06918912, "Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure". Retrieved via MORVS 2026-11-02 from https://api.morvs.ai/clinical/NCT06918912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*